Operational results increased 3.9 percent and the negative impact of currency was 4.5 percent.

Domestic sales increased 7.4 percent. International sales decreased 6.7 percent, reflecting operational growth of 1.2 percent and a negative currency impact of 7.9 percent.

Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.7 percent, domestic sales increased 10.7 percent and international sales increased 3.6 percent.

Worldwide sales for the full-year 2014 were $74.3 billion, an increase of 4.2 percent versus 2013. Operational results increased 6.1 percent and the negative impact of currency was 1.9 percent.

Domestic sales increased 9.0 percent. International sales increased 0.4 percent, reflecting operational growth of 3.7 percent and a negative currency impact of 3.3 percent.

Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 8.0 percent, domestic sales increased 11.6 percent and international sales increased 5.1 percent.

"2014 was a strong year for us, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our medical devices business and are continuing our market leadership with iconic brands in our consumer business," said Mr Alex Gorsky, chairman and CEO, J&J.